Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study expanded its locations to 44 sites across multiple countries, adding Busan (South Korea), Michalovce (Slovakia), Cebu (Philippines), San Luis Potosí City (Mexico), and Mexico City (Mexico). This broadens geographic participation and potential enrollment for the trial.SummaryDifference0.6%

- Check15 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This update appears to reflect behind-the-scenes maintenance rather than changes to study details.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision label was updated from v3.6.1 to v3.6.3, indicating a newer deployment of the page template.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision: v3.6.1 replaces the previous v3.6.0 on the page. This indicates a small update to the page’s revision metadata rather than changes to the study content.SummaryDifference0.0%

- Check58 days agoChange DetectedThe page gains new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment note indicating recruitment is closed; the Intervention/Treatment header is standardized, and the revision note updates from v3.5.5 to v3.6.0.SummaryDifference0.3%

- Check65 days agoChange DetectedStudy locations were updated to reflect a new Blacksburg, VA site (ZIP 24060) and the removal of the previous ZIP 24014. This change updates the geographic availability of trial sites.SummaryDifference0.2%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.